There is unprecedented momentum in the mitochondrial disease clinical trial landscape, and the patient community plays a vital role in ensuring these trials have the potential to lead to new and effective treatments. This expert series aims to demystify clinical trial participation and answer your most pressing questions. Dr. Amy Goldstein, Clinical Director of the Mitochondrial Medicine Frontier Program will discuss what to expect if you participate in clinical trials, and highlight their importance in the drug approval process, and Chad Glasser, Sr. Director of Clinical Research at Tisento Therapeutics, will discuss the actively recruiting PRIZM MELAS study.
There was much discussion about current research in FAODs at our recent International Metabolic conference last month. Reneo Pharmaceuticals recently released positive results from...
The annual mito town meeting is our way of kicking off the new year by sharing all that we have in store for the...
Dr. Fran Kendall of VMP Genetics discusses “Is it really Mito? When an alternative diagnosis should be considered.” Talking points include: Clinical red flags...
